Tuesday, July 23, 2019
In the NEWS: The New Kidney Health Order
Few weeks ago, there was an executive order signed to advance kidney health in the US. This is an historic event for the field of Nephrology and for kidney patients. The above image is a visual abstract that summarizes the changes that might be coming in 2020. This image is courtesy of Dr Tejas Desai @nephondemand
The goal of this order is to increase home dialysis options, increase organ transplantation and promote kidney health and keep patients "away from dialysis". In addition, several incentives have been built in to allow for improved compensation for physicians and what looks like better options for patients. What does this mean for Nephrology?- Time will tell but this is a huge improvement in terms of patient care and patient choices. Hope this also sparks some more interest in the field of nephrology where we are still struggling for trainees.
Saturday, July 13, 2019
Friday, June 28, 2019
Topic Discussion: Amyloidosis and Renal Infarction
Usually when we
think of amyloidosis in the kidney- we think of paraprotein mediated
amyloidosis (AL or AH) leading to nephrotic syndrome and in some rare cases-
vascular amyloid presenting as AKI.
A
recent study published in Mayo Clinic Proceedings suggests that renal
infarction might be a common finding in patients with cardiac amyloidosis. Three groups of patients were
identified according to the underlying amyloidosis disorder: AL amyloidosis in
24 patients, mutated-transthyretin amyloidosis in 24 patients, and wild-type
transthyretin amyloidosis in 39 patients. Patients with AL amyloidosis had
significantly higher N-terminal pro-B-type natriuretic peptide levels (P=.02) and were more
likely to have nephrotic syndrome (P<.001). Renal
infarction was detected in 18 patients (20.7%), at similar frequencies in the
various groups. The likelihood of RI diagnosis was 47.1% (8 of 17) in the
presence of AKI and 14.5% (10 of 69) in its absence (P=.003). Renal infarction
(defined by defect(s) on the DSMA scan) was reported in 20.7% of patients with
and 25% without evidence of cardiac amyloidosis. Prior studies
have not really shown any association like this before of amyloidosis and
infarction. Renal
infarcts were described in an autopsy study in 3 kidneys that had either
cast nephropathy, plasma cell nodules, or autolysis but not with amyloid
deposits. Dang et al interesting are reporting is a high
percentage of abnormal DSMA scans in patients with wild-type
transthyretin amyloidosis (wtATTR) and mutant
transthyretin amyloidosis (mATTR) amyloidosis.
These findings are
intriguing. The 20% to 25% prevalence reported by Dang and colleagues was
therefore unexpected. Renal
involvement in ATTR is thought to be rare, especially in patients with
wtATTR amyloidosis. Recent drugs used to treat this form of amyloidosis might lead to a
glomerulonephritis( my
recent post). The finding from the current study suggests that we may be
vastly underestimating the prevalence of kidney involvement in ATTR amyloidosis. These patients usually don’t
present with nephrotic range proteinuria but more with AKI and subacute AKI.
Perhaps, instead of labeling all of these as cardio-renal syndrome, we should
consider looking for renal infarction in these patients. And as I have always thought about ruling out amyloidosis in young
males who present with renal infarction, I usually stop at AL-AH amyloidosis
testing. Given the above findings, perhaps an amyloid scan to look for wtATTR
and mATTR might be important as perhaps renal infarction could be a potential
relationship here.
Quite an interesting association!!
Thursday, June 20, 2019
Topic Discussion: Tumor Lysis Syndrome with immunotherapy
At this point the nephrology and oncology community is very
aware of the AIN, glomerular diseases including vasculitis and ATN seen with check point inhibitors…
but we might not be aware of tumor lysis syndrome that this drug can entice in
certain patients.
In the last 2 years, I found several published reports of
TLS with check point inhibitors.
Here is a table I created to help with the theme on this one
|
Immunotherapy
|
Age
|
Gender
|
Cancer type
|
Time to TLS
|
Dialysis needed?
|
Outcome
|
Reference
|
|
Nivolumab
|
76
|
Male
|
Melanoma
|
5
|
Yes
but declined
|
Disease
progression-death
|
|
|
Atezolizumab
|
77
|
Female
|
GU
cancer
|
14
|
Yes
|
Disease
progression-death
|
|
|
Atezolizumab
|
-
|
-
|
Solid
tumor
|
-
|
-
|
-
|
|
|
Atezolizumab
|
-
|
-
|
Solid
tumor
|
-
|
-
|
-
|
|
|
Ipilumumab
|
73
|
Male
|
Melanoma
|
6
|
No
|
Death
|
|
|
Nivolumab
|
74
|
Male
|
RCC
|
2
|
No
|
Death
|
|
Based on this, it is seen with PD-1, PDL1 and CTLA4
inhibitors and melanoma and urological cancers. A recent review in JON
showed a case of a patient getting TLS with melanoma. So it’s hard to tell if these agents are
causing it or is it the burden of tumor- usually solid tumors in these cases.
Saturday, June 15, 2019
Concept map: Hyponatremia in the cancer patient
This concept map was adapted and inspired by Umut Selamet and Ala Abudayyeh, both onconephrologists.
Labels:
concept maps,
hyponatremia,
natremias,
onco nephrology
Sunday, June 9, 2019
Consult Rounds: Causes of Osmotic Demyelination unrelated to hyponatremia correction
Osmotic Demyelination syndrome (ODS) is classically been associated with rapid correction of hyponatremia. But sometimes, in some rare cases, we observe other causes of this syndrome.
Here is a list that encompasses other known causes of ODS
Hyperglycemia
Hypernatremia( acute formation)
Hypoglycemia
Hypokalemia( this is well known entity causing it)
Alcoholism( This is probably the most important one)
Liver disease and liver transplantation
Malnutrition( another important one)
Hypophosphatemia
Use of CNI( not sure of the mechanism of this one)
Lithium use
This article from AJKD is an amazing reference.
Here is a list that encompasses other known causes of ODS
Hyperglycemia
Hypernatremia( acute formation)
Hypoglycemia
Hypokalemia( this is well known entity causing it)
Alcoholism( This is probably the most important one)
Liver disease and liver transplantation
Malnutrition( another important one)
Hypophosphatemia
Use of CNI( not sure of the mechanism of this one)
Lithium use
This article from AJKD is an amazing reference.
Thursday, June 6, 2019
Detective Nephron: Next Venture
Check out the next episode of Detective Nephron in ASN Kidney Newshttps://www.kidneynews.org/kidney-news/fellows-corner/detective-nephron/detective-nephron-june-2019
Subscribe to:
Posts (Atom)


